ReviewBiomarkers in cancer2017
Biomarkers for Hepatocellular Carcinoma.
Review in Biomarkers in cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- Serum miR-375 Levels Are Closely Related to Disease Progression from HBV Infection to HBV-Related Hepatocellular Carcinoma.BioMed research international · 2020Trial
- Unraveling risk factors and transcriptomic signatures in liver cancer progression and mortality through machine learning and bioinformatics.Briefings in functional genomics · 2026Article
- Effect of AFP and PIVKA-II secretion status on prognosis of advanced hepatocellular carcinoma patients receiving TACE combined with systemic therapy.BMC cancer · 2025Article
- The role of lipophagy in liver cancer: mechanisms and targeted therapeutic interventions.Frontiers in cell and developmental biology · 2025Review
- Diagnostic value of expressions of cancer stem cell markers for adverse outcomes of hepatocellular carcinoma and their associations with prognosis: A Bayesian network meta‑analysis.Oncology letters · 2024Article
- Identification of Bioactive and Anticancer Properties of Bidens Pilosa in-vitro Evidence.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- PGK1 is a potential biomarker for early diagnosis and prognosis of hepatocellular carcinoma.Oncology letters · 2024Article
- Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.Clinical and molecular hepatology · 2023Review
- Key Members of the CmPn as Biomarkers Distinguish Histological and Immune Subtypes of Hepatic Cancers.Diagnostics (Basel, Switzerland) · 2023Article
- A new portable toluidine blue/aptamer complex-on-polyethyleneimine-coated gold nanoparticles-based sensor for label-free electrochemical detection of alpha-fetoprotein.Frontiers in bioengineering and biotechnology · 2023Article
- Construction of a co-expression network and prediction of metastasis markers in colorectal cancer patients with liver metastasis.Journal of gastrointestinal oncology · 2022Article
- Review
- Smart nanomaterials for cancer diagnosis and treatment.Nano convergence · 2022Review
- Review
- Generation of An Induced Pluripotent Stem Cell Line from Human Liver Fibroblasts from A Patient with Combined Hepatocellular-Cholangiocarcinoma.Cell journal · 2022Article
- Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.American journal of nuclear medicine and molecular imaging · 2022Review
- Roles of circRNAs in the Tumorigenesis and Metastasis of HCC: A Mini Review.Cancer management and research · 2022Review
- Circulating tumor cells in the early detection of human cancers.International journal of biological sciences · 2022Review
- A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus.Journal, genetic engineering & biotechnology · 2021Article
- Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning.BMC cancer · 2021Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis prediction. Furthermore, it might represent certain therapeutic interventions through some combinations of biomarkers. Here, we review on our current understanding of HCC biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.